Table 3

Hematologic and serologic parameters Day -14 to end of treatment (EOT)

Patient #

White blood cells

(× 109/l)

RR 3.9-10.7

Absolute lymphocytes

(× 109/l)

RR 0.9-4.3

Absolute neutrophils

(× 109/l)

RR 2.0-7.2


Day

-14

Day 1

Day 14 (± 1)

EOT

Day

-14

Day 1

Day 14 (± 1)

EOT

Day

-14

Day 1

Day 14 (± 1)

EOT


2

11.2

6.0

8.3

3.8

1.7

1.6

1.7

2.0

8.9

4.1

6.4

1.6L1


8

6.3

15.1

12.4

8.1

0.8L2

0.9

1.3

1.0

5.0

13.7

10.6

7.0


3

5.7

11.1

8.1

4.7

0.9

0.7L2

0.5L2

0.2L3

4.4

10.1

7.4

4.3


5

2.8L2

15.6

N/A

N/A

1.0

3.4

N/A

N/A

1.6L1

10.6

N/A

N/A


13

14.7

5.6

8.5

7.6

1.5

0.7L2

0.5L3

0.7L2

13.1

4.7

7.8

6.5


14

15.5a

15.2

8.3b

7.1

0.9a

1.8

0.8L1, b

0.8L1

13.7a

12.9

7.0b

5.7


CD4+ (cells/μl) [%]

RR 404-1612 [33-58]

Complement C3 (g/l)

RR 0.9-1.8

Anti-dsDNA (IU/ml)

< 30.0, negative; 30-75, borderline; > 75, positive


Patient #

Day 1

Day 28 (± 2)

EOT

Day 1

Day 14 (± 1)

EOT

Day

-14

Day 1

Day 14 (± 1)

EOT


2

489 [25.8L]

1731 [34.1]

980 [44.6]

0.686L

0.904

0.721L

917.2

375.7

168.1

463.9


8

277L2 [23.5L]c

273L2 [29.7L]

195L3 [24.0L]

0.915

1.150

1.070

325.5

306.1

97.6

20.1


3

N/A

56L3 [13.7L]

45L4 [21.4L]

0.533L

0.800L

0.906

155.3

77.6

37.5

< 12.3


5

529 [22.1L]

809 [30.1L]

603 [46.8]

1.030

1.630

1.700

56.7

43.0

34.3

12.6


13

240L2 [38.7]

95L3 [23.8L]

163L3 [19.3L]

0.462L

0.717

0.909

87.5

26.0

13.0

12.7


14

135L3 [19.1L]

N/A

158L3 [19.9L]

0.434L

0.541b

0.609L

349.6

88.1

28.8b

20.1


Patients #2 and #8 randomized to placebo; Patients #3, #5, #13 and #14 randomized to atacicept 150 mg subcutaneously twice weekly (4 weeks), then 150 mg weekly (48 weeks). N/A, not available; RR, reference range. Values > ULN indicated in italics; LValues < LLN, with Grade (1 to 4), where applicable. aMeasured Day -10; bMeasured Day 18; cMeasured Day 4.

Ginzler et al. Arthritis Research & Therapy 2012 14:R33   doi:10.1186/ar3738

Open Data